Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma.
Information on specificities of serological responses against tumor cells in cutaneous lymphoma patients is relatively restricted. To advance the knowledge of serological immune responses against and to assess the scope of tumor antigenicity of cutaneous lymphoma, 1- and 2-dimensional Western blot analyses with sera from patients were combined with proteomics-based protein identification. Testing sera from 87 cutaneous lymphoma patients by 1-dimensional Western blot analysis, 64 cases of seroreactivity against lymphoma cells were found. The positive responses were relatively weak, restricted to few antigens in each case, and heterogeneous. To identify the antigens, proteins of the mycosis fungoides cell line MyLa and primary tumor cells were separated by 2-dimensional gel electrophoresis, Western-blotted and probed with heterogeneous and autologous patient sera. The antigens were identified from silver-stained replica gels by MALDI-TOF mass spectrometry. 14 different antigens were assigned and identified with this proteome-serological approach. Only one, vimentin, had been reported before, the other 13 are new antigens for cutaneous lymphomas.
Forgber
Michael
M
Department of Dermatology, Venerology and Allergy, Charité - Universitätsmedizin Berlin, Humboldt University, Berlin, Germany.
Gellrich
Sylke
S
Sharav
Tumenjargal
T
Sterry
Wolfram
W
Walden
Peter
P
D000951:Antigens, Neoplasm / Q000097:blood*; D045744:Cell Line, Tumor; D006801:Humans; D008223:Lymphoma / Q000097:blood* / Q000276:immunology*; D009182:Mycosis Fungoides / Q000097:blood / Q000276:immunology; D020543:Proteome / Q000378:metabolism*; D012698:Serologic Tests; D012878:Skin Neoplasms / Q000097:blood* / Q000276:immunology*
D000951:Antigens, Neoplasm; D020543:Proteome